Janux Therapeutics Inc (JANX)

NASDAQ
Currency in USD
25.49
+1.04(+4.25%)
Closed·
After Hours
25.00-0.49(-1.92%)
·
JANX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
JANX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
24.6925.61
52 wk Range
22.4871.71
Key Statistics
Edit
Prev. Close
24.45
Open
24.73
Day's Range
24.69-25.61
52 wk Range
22.48-71.71
Volume
917.83K
Average Volume (3m)
918.09K
1-Year Change
-38.81%
Book Value / Share
17.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
JANX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
84.12
Upside
+230.02%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

Janux Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Janux Therapeutics Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.

Compare JANX to Peers and Sector

Metrics to compare
JANX
Peers
Sector
Relationship
P/E Ratio
−19.4x−0.6x−0.5x
PEG Ratio
1.480.000.00
Price/Book
1.5x1.8x2.6x
Price / LTM Sales
161.6x9.5x3.1x
Upside (Analyst Target)
237.4%180.0%45.7%
Fair Value Upside
Unlock17.1%5.7%Unlock

Analyst Ratings

12 Buy
1 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 84.12
(+230.02% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-0.38 / -0.37
Revenue / Forecast
-- / 363.64K
EPS Revisions
Last 90 days

JANX Income Statement

FAQ

What Is the Janux Therapeutics (JANX) Stock Price Today?

The Janux Therapeutics stock price today is 25.49.

What Stock Exchange Does Janux Therapeutics Trade On?

Janux Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Janux Therapeutics?

The stock symbol for Janux Therapeutics is "JANX."

What Is the Janux Therapeutics Market Cap?

As of today, Janux Therapeutics market cap is 1.51B.

What Is Janux Therapeutics's Earnings Per Share (TTM)?

The Janux Therapeutics EPS (TTM) is -1.37.

When Is the Next Janux Therapeutics Earnings Date?

Janux Therapeutics will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is JANX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Janux Therapeutics Stock Split?

Janux Therapeutics has split 0 times.

How Many Employees Does Janux Therapeutics Have?

Janux Therapeutics has 91 employees.

What is the current trading status of Janux Therapeutics (JANX)?

As of 09 Jul 2025, Janux Therapeutics (JANX) is trading at a price of 25.49, with a previous close of 24.45. The stock has fluctuated within a day range of 24.69 to 25.61, while its 52-week range spans from 22.48 to 71.71.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.